Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding the role of insulin resistance to the earliest phases of cognitive decline: Preliminary evidence.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Late-onset severe axonal polyneuropathy in mut0 methylmalonic acidemia after liver-kidney transplantation: a genotype-informed case report.

BMC neurology·2026
Same author

Integrated electrophysiological, cellular, and pharmacological profiling reveals variant-specific mechanisms in SCN4A-related myotonia.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Ataxia With Vitamin E Deficiency Syndrome and a Novel <i>TTPA</i> Variant: A Paired Case Report.

Neurology. Genetics·2026
Same author

Safety and Tolerability of Givinostat: Evidence From Real-World and Clinical Practice.

Annals of clinical and translational neurology·2026
Same author

Expanding the genetic landscape of Dusty Core Disease: new RYR1 variants in Italian patients.

European journal of human genetics : EJHG·2026

Related Experiment Video

Updated: Apr 17, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.2K

Therapeutic development in amyotrophic lateral sclerosis.

Monica Bucchia1, Agnese Ramirez1, Valeria Parente1

  • 1Dino Ferrari Centre, Department of Neurological Sciences, University of Milan, IRCCS Foundation Ca' Granda Maggiore Hospital Policlinico, Milan, Italy.

Clinical Therapeutics
|February 11, 2015
PubMed
Summary

Despite ongoing research into novel molecular targets and therapies for amyotrophic lateral sclerosis (ALS), no treatment has proven effective yet. However, recent advancements in understanding ALS pathogenesis may accelerate the development of future effective treatments.

Keywords:
amyotrophic lateral sclerosisclinical trialsmolecular targetsmotor neuron diseasesmall molecules

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.9K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

356

Related Experiment Videos

Last Updated: Apr 17, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

10.2K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.9K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

356

Area of Science:

  • Neuroscience
  • Neurology
  • Genetics

Background:

  • Amyotrophic lateral sclerosis (ALS) is a fatal adult motor neuron disease with limited treatment options.
  • Current management includes supportive care and riluzole, which offers modest survival benefits.

Purpose of the Study:

  • To review preclinical and clinical advances in amyotrophic lateral sclerosis (ALS) research.
  • To summarize emerging therapeutic strategies and their molecular targets for ALS.

Main Methods:

  • Systematic literature review of PubMed.
  • Analysis of ALS Therapy Development Institute website.
  • Inclusion of selected ALS clinical trials from ClinicalTrials.gov.

Main Results:

  • Recent research focuses on understanding ALS genetic and molecular mechanisms.
  • Therapeutic targets include kinases, inflammation, gene silencing, and cell-based therapies.
  • Clinical trials are evaluating the safety and efficacy of various pharmacologic, gene, and cellular therapies for ALS progression.

Conclusions:

  • Currently, no ALS therapeutic approach is definitively effective.
  • Recent findings offer promise for accelerating the discovery of effective ALS treatments.